Influence of chronic kidney disease and its severity on the efficacy of semaglutide in type 2 diabetes patients: a multicenter real-world study

OBJECTIVES: Semaglutide is a glucagon-like peptide 1 receptor agonist that improves glycemic control and achieves weight loss in type 2 diabetes (T2D) patients. Subcutaneous (s.c.) semaglutide at 1 mg once weekly (OW) is safe in T2D patients with chronic kidney disease (CKD). Whether or not CKD and...

Descripción completa

Detalles Bibliográficos
Autores principales: García de Lucas, María Dolores, Caballero, Irene, Fernández-García, José Carlos, Domínguez-Rodríguez, Manuel, Moreno-Moreno, Paloma, Jiménez-Millán, Anabel, Botana-López, Manuel, Avilés, Beatriz, Merino-Torres, Juan Francisco, Soto, Alfonso, Tejera, Cristina, Morales, Cristóbal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10634592/
https://www.ncbi.nlm.nih.gov/pubmed/37955013
http://dx.doi.org/10.3389/fendo.2023.1240279

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10634592/
https://www.ncbi.nlm.nih.gov/pubmed/37955013
http://dx.doi.org/10.3389/fendo.2023.1240279

Ejemplares similares